Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the results from the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment.

Ticker(s): PTGX

Who's the expert?

Institution: Private Practice

Board certified medical oncologist and hematologist
Expertise in breast cancer, head and neck cancer, lung cancer, leukemia
Completed a number of oncology manuscripts and presentations
Manages 56 patients with PNH and prescribed Epaveli to 29 patients

Interview Goal

This interview seeks to delve into the significant findings and clinical advancements presented by Protagonist Therapeutics, Inc. regarding their innovative drug, Rusfertide (PTG-300), a hepcidin mimetic. The primary focus will be on assessing the efficacy, safety, and potential transformative impact of Rusfertide in the treatment of polycythemia vera (PV), based on the results from the 2-year follow-up data of the REVIVE study and other relevant research.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.